Literature DB >> 2949919

Altered recognition of hypoglycaemic symptoms in type I diabetes during intensified control with continuous subcutaneous insulin infusion.

I Lager, S Attvall, G Blohmé, U Smith.   

Abstract

The effect of intensified metabolic control obtained with continuous subcutaneous insulin infusion (CSII) on the frequency and symptoms of hypoglycaemia was studied in type I diabetic patients. The reproducibility of the questionnaire used to evaluate the hypoglycaemic symptoms was verified in a control group receiving unchanged conventional insulin therapy for 2 months. Metabolic control was significantly improved during CSII (HbA1c 6.8 +/- 0.4% versus 8.7 +/- 0.7%, normal range up to 5.4%) in all patients while no change was seen in the control group. The results of frequent self glucose monitoring showed that the incidence of low glucose levels (below 3.5 mmol/l) increased about threefold in the CSII group. Awareness of hypoglycaemia was clearly changed during CSII with less pronounced adrenergic symptoms while no alterations were found in the group with unchanged metabolic control. These results emphasize the importance of regular self glucose monitoring during CSII and of informing the patients that their hypoglycaemic symptoms may change during intensified control.

Entities:  

Mesh:

Year:  1986        PMID: 2949919     DOI: 10.1111/j.1464-5491.1986.tb00772.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  10 in total

1.  Neurophysiological changes during insulin-induced hypoglycaemia and in the recovery period following glucose infusion in type 1 (insulin-dependent) diabetes mellitus and in normal man.

Authors:  G Tallroth; M Lindgren; G Stenberg; I Rosen; C D Agardh
Journal:  Diabetologia       Date:  1990-05       Impact factor: 10.122

2.  Orexin signaling is necessary for hypoglycemia-induced prevention of conditioned place preference.

Authors:  Oleg Otlivanchik; Nicole M Sanders; Ambrose Dunn-Meynell; Barry E Levin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-28       Impact factor: 3.619

Review 3.  Human insulin.

Authors:  J Pickup
Journal:  BMJ       Date:  1989-10-21

4.  Lack of preservation of higher brain function during hypoglycaemia in patients with intensively-treated IDDM.

Authors:  A Maran; J Lomas; I A Macdonald; S A Amiel
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

Review 5.  Adverse effects of exogenous insulin. Clinical features, management and prevention.

Authors:  A W Patrick; G Williams
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

6.  Intensified conventional insulin treatment and neuropsychological impairment.

Authors:  P Reichard; A Britz; U Rosenqvist
Journal:  BMJ       Date:  1991-12-07

7.  Effects of previous glycaemic control on the onset and magnitude of cognitive dysfunction during hypoglycaemia in type 1 (insulin-dependent) diabetic patients.

Authors:  D Ziegler; A Hübinger; H Mühlen; F A Gries
Journal:  Diabetologia       Date:  1992-09       Impact factor: 10.122

8.  Double blind clinical and laboratory study of hypoglycaemia with human and porcine insulin in diabetic patients reporting hypoglycaemia unawareness after transferring to human insulin.

Authors:  A Maran; J Lomas; H Archibald; I A Macdonald; E A Gale; S A Amiel
Journal:  BMJ       Date:  1993-01-16

9.  Counterregulatory hormonal responses to hypoglycaemia in type 1 (insulin-dependent) diabetes: evidence for diminished hypothalamic-pituitary hormonal secretion.

Authors:  B M Frier; B M Fisher; C E Gray; G H Beastall
Journal:  Diabetologia       Date:  1988-07       Impact factor: 10.122

10.  Modest decrements in plasma glucose concentration cause early impairment in cognitive function and later activation of glucose counterregulation in the absence of hypoglycemic symptoms in normal man.

Authors:  P De Feo; V Gallai; G Mazzotta; G Crispino; E Torlone; G Perriello; M M Ventura; F Santeusanio; P Brunetti; G B Bolli
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.